![Kyle Kuvalanka](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kyle Kuvalanka
Finanzdirektor/CFO bei
AKTIS ONCOLOGY, INC.
Profil
Kyle D.
Kuvalanka is Chief Financial Officer at Aktis Oncology, Inc. since 2025.
Former roles include Independent Director at IMV, Inc. from 2021 to 2023; Chief Operating & Financial Officer at Goldfinch Bio, Inc. from 2020 to 2023; Chief Financial Officer & Chief Business Officer at Rome Therapeutics, Inc.; Chief Operating, Financial & Accounting Officer at Syros Pharmaceuticals, Inc. from 2015 to 2017; CFO, Treasurer, CAO & Chief Business Officer at Blueprint Medicines Corp.
from 2013 to 2015; Vice President-Strategy & Business Development at Millennium Pharmaceuticals, Inc. from 2012 to 2013.
Education includes undergraduate studies at Wesleyan University and an MBA from The Wharton School of the University of Pennsylvania.
Aktive Positionen von Kyle Kuvalanka
| Unternehmen | Position | Beginn |
|---|---|---|
| AKTIS ONCOLOGY, INC. | Finanzdirektor/CFO | 01.11.2025 |
Ehemalige bekannte Positionen von Kyle Kuvalanka
| Unternehmen | Position | Ende |
|---|---|---|
| IMV INC. | Direktor/Vorstandsmitglied | 01.09.2023 |
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease | Finanzdirektor/CFO | 01.04.2023 |
| SYROS PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 22.09.2017 |
| BLUEPRINT MEDICINES CORPORATION | Finanzdirektor/CFO | 18.09.2015 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Corporate Officer/Principal | 01.09.2013 |
Ausbildung von Kyle Kuvalanka
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
32
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Wesleyan University
 Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IMV, Inc.
 IMV, Inc. BiotechnologyHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Syros Pharmaceuticals, Inc.
 Syros Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which developing care for the frontline treatment of patients with hematologic malignancies | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease | Health Technology |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases | Health Technology |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers radiopharmaceuticals to treat tumor cancers | Health Technology |
